Prevas AB Series B
Prevas AB provides technical solutions in Sweden, Denmark, Finland, and internationally. The company offers embedded systems and intelligent sensors, enterprise asset management maintenance solutions, field service, industrial digitalization, internet of things, product development of medical technology products, product lifecycle management, and smart services; and cyber security, electronics de… Read more
Prevas AB Series B (0H2J) - Total Liabilities
Latest total liabilities as of September 2021: Skr350.49 Million SEK
Based on the latest financial reports, Prevas AB Series B (0H2J) has total liabilities worth Skr350.49 Million SEK as of September 2021.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Prevas AB Series B - Total Liabilities Trend (2016–2020)
This chart illustrates how Prevas AB Series B's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Prevas AB Series B Competitors by Total Liabilities
The table below lists competitors of Prevas AB Series B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oncopeptides AB (publ)
PINK:ONPPF
|
USA | $179.25 Million |
|
Stratec SE
PINK:STSEY
|
USA | $191.16 Million |
|
AMIA Co. Ltd.
TW:8438
|
Taiwan | NT$1.09 Billion |
|
Central Plains Bancshares, Inc. Common Stock
NASDAQ:CPBI
|
USA | $447.98 Million |
|
Sanstar Ltd
NSE:SANSTAR
|
India | ₹1.02 Billion |
|
Imas Makina Sanayi AS
IS:IMASM
|
Turkey | TL1.62 Billion |
|
MKH Bhd
KLSE:6114
|
Malaysia | RM1.23 Billion |
|
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
|
USA | $60.14 Million |
Liability Composition Analysis (2016–2020)
This chart breaks down Prevas AB Series B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prevas AB Series B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prevas AB Series B (2016–2020)
The table below shows the annual total liabilities of Prevas AB Series B from 2016 to 2020.
| Year | Total Liabilities | Change |
|---|---|---|
| 2020-12-31 | Skr224.71 Million | +5.74% |
| 2019-12-31 | Skr212.52 Million | -2.36% |
| 2018-12-31 | Skr217.65 Million | +0.30% |
| 2017-12-31 | Skr217.00 Million | -3.61% |
| 2016-12-31 | Skr225.12 Million | -- |